Oct 1(Reuters) - Innate Pharma:
* REPORTED ON SATURDAY IPH4102 PHASE 1 RESULTS IN ADVANCED CUTEANOUS T CELL LYMPHOMA
* RESULTS SHOW HIGH RESPONSE RATE AND LONG PROGRESSION-FREE SURVIVAL
Source text for Eikon:
Further company coverage: (Gdynia Newsroom)